Chronic Inflammatory Response Syndrome (CIRS) is a multi-system illness triggered by exposure to biotoxins — primarily mold (water-damaged buildings), Lyme disease, post-viral illness, and ciguatera. In genetically susceptible individuals (approximately 25% of the population carry the HLA-DR variants that prevent normal biotoxin clearance), a single significant exposure can trigger a self-perpetuating inflammatory cascade that doesn't resolve when the exposure ends.

The result is a condition that standard medicine consistently fails to diagnose — because standard blood panels almost always come back normal. Meanwhile the patient experiences a constellation of symptoms that looks like chronic fatigue, fibromyalgia, depression, cognitive decline, and autoimmune disease simultaneously.

The MARCONS connection is one of the most important and underrepresented aspects of CIRS. MARCONS (Multiple Antibiotic Resistant Coagulase Negative Staph) colonizes the nasal passages in many CIRS patients — and actively destroys α-MSH, the body's primary anti-inflammatory hormone. This creates a vicious cycle: CIRS depletes α-MSH, which allows MARCONS to thrive, which further destroys α-MSH, which deepens the inflammatory cascade.

• ★ Anchor — Immune Modulation Thymosin Alpha-1 (Tα1) Thymosin Alpha-1 is the primary immune modulator in the CIRS protocol. It restores appropriate immune regulation — neither suppressing nor over-activating the immune response, but normalizing the dysregulated TGF-β1 driven inflammatory cascade that defines CIRS. It also directly addresses the elevated TGF-β1 that is one of CIRS's most consistent biomarkers. Used in courses alongside KPV for the full immune restoration effect.
• ★ Anchor — α-MSH Restoration KPV (Lys-Pro-Val) KPV is a tripeptide fragment of α-MSH — the anti-inflammatory hormone destroyed by MARCONS in CIRS patients. KPV directly restores the α-MSH signaling pathway, breaking the MARCONS-α-MSH destruction cycle. Critical protocol note: KPV must be run for a minimum of 4 months without cycling off early. The most common practitioner error in CIRS treatment is discontinuing KPV before the α-MSH pathway is fully restored — which allows the cycle to re-establish.
• Gut & systemic repair BPC-157 CIRS reliably damages gut integrity — and gut permeability is both a consequence and a driver of ongoing systemic inflammation. BPC-157 repairs the gut lining, reduces intestinal inflammation, and addresses the leaky gut component of CIRS that keeps the inflammatory cycle running. Also relevant for the musculoskeletal pain that commonly accompanies CIRS.
• Systemic tissue repair TB-4 Fragment (Thymosin Beta-4 Fragment) Supports systemic tissue repair and immune modulation. Works synergistically with BPC-157 for comprehensive healing. Raises underactive immune response — relevant to the immune imbalance driving CIRS.
• Sleep foundation — nearly always indicated Epithalon CIRS patients almost universally experience disrupted restorative sleep. Epithalon restores deep sleep and REM through pineal gland support — which also supports the same α-MSH-related pathway disrupted by CIRS. Additionally addresses the accelerated telomere shortening driven by chronic systemic inflammation.